Description: Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of coronavirus disease 2019; and Epclusa, Harvoni, Vosevi, Vemlidy, and Viread for the treatment of liver diseases. It also offers Yescarta, Tecartus, Trodelvy, and Zydelig products for the treatment of hematology, oncology, and cell therapy patients. In addition, the company provides Letairis, an oral formulation for the treatment of pulmonary arterial hypertension; Ranexa, an oral formulation for the treatment of chronic angina; and AmBisome, a liposomal formulation for the treatment of serious invasive fungal infections. Gilead Sciences, Inc. has collaboration agreements with Arcus Biosciences, Inc.; Pionyr Immunotherapeutics Inc.; Tizona Therapeutics, Inc.; Tango Therapeutics, Inc.; Jounce Therapeutics, Inc.; Galapagos NV; Janssen Sciences Ireland Unlimited Company; Japan Tobacco, Inc.; Gadeta B.V.; Bristol-Myers Squibb Company; Dragonfly Therapeutics, Inc.; and Merck & Co, Inc. The company was incorporated in 1987 and is headquartered in Foster City, California.
Home Page: www.gilead.com
333 Lakeside Drive
Foster City,
CA
94404
United States
Phone:
650 574 3000
Officers
| Name | Title |
|---|---|
| Mr. Daniel P. O'Day | Chairman & CEO |
| Mr. Andrew D. Dickinson | Exec. VP & CFO |
| Ms. Johanna Mercier | Chief Commercial Officer |
| Dr. Merdad V. Parsey M.D., Ph.D. | Chief Medical Officer |
| Ms. Diane E. Wilfong | Sr. VP, Corp. Controller & Chief Accounting Officer |
| Ms. Jacquie Ross C.F.A. | VP of Investor Relations |
| Ms. Deborah H. Telman | Exec. VP of Corp. Affairs, Gen. Counsel & Corp. Sec. |
| Ms. Jyoti K. Mehra | Exec. VP of HR |
| Dr. Michael Quigley Ph.D. | Sr. VP of Research Biology |
| Dr. Linda Slanec Higgins Ph.D. | Sr. VP & Head of External Innovation |
Exchange: F
Country: DE
Currency: Euro (€)
| Forward PE: | 13.0719 |
|---|---|
| Trailing PE: | 32.1036 |
| Price-to-Book MRQ: | 5.2739 |
| Price-to-Sales TTM: | 3.7531 |
| IPO Date: | |
| Fiscal Year End: | December |
| Full Time Employees: | 14400 |